Molecular Insights and Novel Therapies for Lymphoproliferative Disorders
International Journal of Molecular Sciences · 02.06.2026 · 27 (11) · 5026
DOI: 10.3390/ijms27115026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.06.2026. Verfasst von Shucen Wan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Penn State Milton S. Hershey Medical Center, 500 University Dr, Hershey, PA 17033, USA. Hauptthemen laut MEDLINE: Lymphoproliferative Disorders. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hematological malignancies encompass a broad spectrum of relatively rare cancers with diverse biological and clinical characteristics that are capable of affecting individuals across all age groups, though certain subtypes show a predilection for specific age ranges. Advances in next-generation sequencing have greatly enhanced our understanding of the molecular and genetic basis of these diseases, while epigenetic, transcriptional, and proteomic analyses have further clarified their pathogenesis. These developments have shaped the classification and treatment of lymphoma. Updated classification frameworks which include the identification of clinically relevant molecular targets have opened the door to a number of targeted agents, each designed to exploit specific vulnerabilities within malignant cells, while stem cell transplantation continues to offer curative potential for eligible patients, with improving safety profiles over time. CAR-T-cell therapy has been extended to multiple blood cancer indications, achieving lasting remissions in patients with previously exhausted treatment options. Bispecific antibodies have further broadened the immunotherapy landscape by redirecting the body’s own T cells against tumor cells, offering a readily available alternative that overcomes many of the practical limitations associated with CAR-T-cell production. The ability to combine these strategies has fundamentally changed what is achievable in blood cancer treatment, with long-term remission now a realistic goal for many patients. This review seeks to outline the core molecular mechanisms underlying lymphoma and leukemia, evaluate currently approved treatment options, discuss significant ongoing clinical trials with practice-changing potential, and explore the prospect of chemotherapy-free approaches in carefully selected patient groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Penn State Milton S. Hershey Medical Center, 500 University Dr, Hershey, PA 17033, USA.
ORCID-Profile: Shucen Wan, Seema Naik
Zitieren
APA
Wan, S., & Naik, S. (2026). Molecular Insights and Novel Therapies for Lymphoproliferative Disorders. International Journal of Molecular Sciences, 27(11), 5026. https://doi.org/10.3390/ijms27115026
Vancouver
Wan S, Naik S. Molecular Insights and Novel Therapies for Lymphoproliferative Disorders. International Journal of Molecular Sciences. 2026;27(11):5026. doi:10.3390/ijms27115026
BibTeX
@article{Wan2026,
author = {Wan, Shucen and Naik, Seema},
title = {Molecular Insights and Novel Therapies for Lymphoproliferative Disorders},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {5026},
doi = {10.3390/ijms27115026}
}
EUVIMED